Latest News and Press Releases

Übernahme stärkt BioNTechs Zelltherapie-Pipeline durch Beschleunigung des Forschungs- und Entwicklungsprogramms für individualisierte Neoantigen-TCR-Zelltherapien für solide Tumore sowie den Ausbau...

Deal strengthens BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adding manufacturing footprint in North...

Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...

TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

RICHMOND, Va., Oct. 28, 2020 (GLOBE NEWSWIRE) -- The Balm In Gilead Inc. is a leader in bringing public health and faith communities together to strategically address health disparities in the...

Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients...